cyclo(leucyl-phenylalanyl): has pronuclear fusion inhibitory activity; isolated from Streptomyces albulus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
cyclo(L-phenylalanyl-L-leucyl) : A member of the class of 2,5-diketopiperazines that is piperazine-2,5-dione in which one hydrogen at position 3 and one hydrogen at position 6 are replaced by benzyl and isobutyl groups (the 3S,6S-diastereomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7076347 |
| CHEMBL ID | 189999 |
| CHEBI ID | 71608 |
| SCHEMBL ID | 2864427 |
| MeSH ID | M0359996 |
| Synonym |
|---|
| cyclo(l-phe-l-leu) |
| CHEMBL189999 |
| chebi:71608 , |
| 7280-77-5 |
| (3s,6s)-3-benzyl-6-(2-methylpropyl)piperazine-2,5-dione |
| l-phenylalanyl-l-leucine diketopiperazine |
| 2,5-piperazinedione, 3-benzyl-6-isobutyl-, (3s,6s)- |
| cyclo(l-leucyl-l-phenylalanyl) |
| (3s,6s)-3-(2-methylpropyl)-6-(phenylmethyl)-2,5-piperazinedione |
| cyclo(leu-phe) |
| 2,5-piperazinedione, 3-(2-methylpropyl)-6-(phenylmethyl)-, (3s-cis)- |
| 2,5-piperazinedione, 3-(2-methylpropyl)-6-(phenylmethyl)-, (3s,6s)- |
| cyclo(leucyl-phenylalanyl) |
| C20519 |
| (3s,6s)-3-benzyl-6-isobutylpiperazine-2,5-dione |
| CFL , |
| cyclo(l-phenylalanyl-l-leucyl) |
| cyclo(l-leu-l-phe) |
| cyclo(-leu-phe) |
| SCHEMBL2864427 |
| cyclo(-l-leu-l-phe) |
| 3-benzyl-6-isobutyl-2,5-piperazinedione # |
| cyclo-(l-leucyl-l-phenylalanyl) |
| mfcd00672388 |
| cyclo(-leu-phe), aldrichcpr |
| AKOS027250806 |
| Q27139751 |
| DTXSID20993602 |
| 3-benzyl-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol |
| CS-0655411 |
| HY-P4617 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| 2,5-diketopiperazines | Any piperazinone that has a piperazine-2,5-dione skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID648931 | Antioxidant activity assessed as superoxide radical scavenging activity at 2.5 mM by electron spin resonance method | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Cyclic dipeptides exhibit potency for scavenging radicals. |
| AID1543354 | Antibiofilm activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining-based assay | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens. |
| AID243882 | Percent inhibition of human calpain 1 at 130 uM; Inhibition within 110% | 2005 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 15, Issue:12 | Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. |
| AID380266 | Antibiotic activity against Bacillus subtilis ATCC 6633 by agar diffusion method | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | A sorbicillinoid urea from an intertidal Paecilomyces marquandii. |
| AID380267 | Antibiotic activity against Escherichia coli ATCC 25922 by agar diffusion method | 2006 | Journal of natural products, Dec, Volume: 69, Issue:12 | A sorbicillinoid urea from an intertidal Paecilomyces marquandii. |
| AID1543335 | Antibiofilm activity against Fusobacterium nucleatum ATCC 25586 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens. |
| AID1543336 | Antibiofilm activity against Porphyromonas gingivalis ATCC 33277 assessed as inhibition of biofilm formation up to 96 ug/mL after 24 hrs by crystal violet staining based assay | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens. |
| AID1543364 | Inhibition of planktonic growth of Streptococcus mutans ATCC 25175 up to 96 ug/mL after 24 hrs relative to control | 2019 | Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12 | Anti-biofilm and anti-adherence properties of novel cyclic dipeptides against oral pathogens. |
| AID648929 | Antioxidant activity assessed as hydroxyl radical scavenging activity at 2.5 mM by electron spin resonance method | 2012 | Bioorganic & medicinal chemistry, Mar-15, Volume: 20, Issue:6 | Cyclic dipeptides exhibit potency for scavenging radicals. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||